COMMUNIQUÉS West-GlobeNewswire

Medtronic Announces FDA Clearance and U.S. Launch of the Accurian Radio Frequency System for Nerve Tissue Ablation

27/02/2019 - 13:01

Medtronic Expands Pain Portfolio with Minimally Invasive Therapy to Support Patients Throughout the Care Continuum DUBLIN - February 27, 2019 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration [...]

Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019

27/02/2019 - 13:00

Conference Call and Webcast Scheduled for Wednesday, March 6 at 8:00 a.m. Eastern Time YARDLEY, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear [...]

Terranueva Raises $278,750 Following Exercise of Rights

27/02/2019 - 13:00

MONTREAL, Feb. 27, 2019 (GLOBE NEWSWIRE) -- TERRANUEVA CORPORATION (“Terranueva”) (CSE: TEQ) announces that it has raised $278,743.04 from its rights offering (the “Rights”), which started on October 30, 2018, while [...]

Terranueva amasse 278 750 $ suite à l’exercice de droits

27/02/2019 - 13:00

MONTRÉAL, 27 févr. 2019 (GLOBE NEWSWIRE) -- CORPORATION TERRANUEVA (« Terranueva » ou la « Société ») (CSE: TEQ) annonce avoir amassé 278 743,04 $ suite à la conclusion de son placement de droits (les « Droits »), ayant [...]

G1 Therapeutics to Host Investor Day 2019 on March 6, 2019

27/02/2019 - 13:00

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host its Investor Day 2019 on Wednesday, March 6 in [...]

Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment

27/02/2019 - 13:00

- Results from the Phase 2 Expansion of ILLUMINATE-204 anticipated to be reported in the 4 th Quarter of 2019 – - December 2018 Interim Update of 34 efficacy evaluable patients demonstrated 32.4% achieved partial [...]

Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint

27/02/2019 - 13:00

ATTRibute-CM study design, which incorporates feedback from the FDA, has the potential to accelerate registration with a 12-month primary endpoint of change in 6-minute walk distance (6MWD), followed by a 30-month [...]

PotBotics Takes Aim at the Vaporizer Market with RYAH -- CFN Media

27/02/2019 - 13:00

Seattle, Washington, Feb. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces [...]

ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

27/02/2019 - 13:00

LEIDEN, The Netherlands & CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the [...]

Verrica Pharmaceuticals Announces Participation in the Cowen and Company 39th Annual Healthcare Conference

27/02/2019 - 13:00

WEST CHESTER, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical [...]

Antares Pharma to Present at the Raymond James & Associates 40th Annual Institutional Investors Conference

27/02/2019 - 13:00

EWING, N.J., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James & Associates 40 th [...]

Delight Announces Availability of its Oasis-RC New Wirelessly Charged Personal Sound Amplification Product (PSAP)

27/02/2019 - 12:25

SEOUL, South Korea, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Delight, a company committed to making hearing aid solutions more accessible for consumers, today announced that its new wirelessly charged personal sound [...]

OraSure Technologies to Present at the Raymond James 40th Annual Institutional Investors Conference

27/02/2019 - 12:00

BETHLEHEM, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, [...]

Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations

27/02/2019 - 11:00

Record Revenue of $229.2 Million and $ 77.3 Million for Full Year and Fourth Quarter 2018 REDUCE-IT™ sNDA Submission Remains on Schedule to be Filed Before the End of Q1 2019 Management to Host Conference Call at 7:30 a [...]

Nexstim Plc Postpones its 2018 Full Year Results Release to Monday 4 March 2019

27/02/2019 - 08:01

Company announcement, Helsinki, 27.02.2019 at 09.00 Finnish time (EET) Nexstim Plc Postpones its 2018 Full Year Results Release to Monday 4 March 2019 Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), the [...]

111, Inc. Announces the Appointment of a New Chief Financial Officer

27/02/2019 - 07:35

SHANGHAI, China, Feb. 27, 2019 (GLOBE NEWSWIRE) -- 111, Inc. (Nasdaq: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, today announced that Mr. Yang Chen has been appointed as [...]

Esperite N.V. (ESP) with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of Bronchopulmonary Dysplasia.

27/02/2019 - 07:17

CF-MEV-132 drug candidate belongs to the CF-MEV family of anti-inflammatory EV drugs produced by The Cell Factory Amsterdam, The Netherlands – 27 February 2019 The Cell Factory and the University of Padova, Italy have [...]

Annual Report 2018: GN delivers on guidance with 13% organic growth and EBITA margin increase – 18% organic growth in Q4 2018

27/02/2019 - 07:00

Financial highlights 2018 GN delivered DKK 10.6 billion revenue with organic growth at 13% EBITA reached DKK 2.0 billion, with an EBITA margin increase of 0.2 percentage points, based on strong execution in GN Hearing [...]

ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019

27/02/2019 - 07:00

Geneva, Switzerland and Boston, MA –February 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]